glp-1 weight loss clinical trials recruiting 📣 NOW RECRUITING: New Research Study We are looking for participants for a Phase 3 trial evaluating a new GLP1 agonists: current and future

A phase II study evaluated the combination of docetaxel and 30 mg/day lycopene in 13 chemotherapy-naive patients with advanced castrate-resistant PCa, resulting in a 50% PSA reduction in 76.9% of participants

For the first time, it has been demonstrated that the above-mentioned MVs could cause upregulation of collagen I1 and collagen III mRNA expression while having no adverse impacts on the survival and proliferation of both MSCs and fibroblasts

It neutralizes free radicals, supports liver detoxification, recycles other antioxidants like vitamins C and E, and protects your mitochondria from oxidative damage

Genetic insights into antioxidant-pathway function can support a more targeted conversation with your provider